Vergelijking

Linaclotid vs. Semax

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

851199-59-2

80714-61-0

Molecuulmassa

1526.74 g/mol

813.92 g/mol

Halfwaardetijd

geen gegevens

0.3 h

Sequentie

geen gegevens

Met-Glu-His-Phe-Pro-Gly-Pro

Werkingsmechanisme

Linaclotid

Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.

Semax

Semax is a tetracosactide fragment analog without hormonal activity at MC2R. Proposed mechanisms include elevation of BDNF and NGF in hippocampus and striatum (in animal models), modulation of dopamine metabolism, and neuroprotective effects via anti-apoptotic pathways. A clear primary receptor is not established.

Bewijsbasis

Hoogste bewijs

Humane RCT

Humane studie

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Linaclotid	Semax
Duitsland	Op recept	Niet goedgekeurd
RU	—	Op recept
Verenigde Staten	Op recept	Niet goedgekeurd

Volledige vermeldingen

Linaclotid

Volledige vermelding →

Semax

Volledige vermelding →

Frequently asked questions

What is the difference between Linaclotid and Semax?: Linaclotid is classified as "Onderzoek (overig)", while Semax is classified as "Onderzoek (overig)". Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Semax: Synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10). Approved in Russia for ischaemic stroke, cognitive function and ADHD in children. Western phase-3 trials absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Linaclotid or Semax?: The highest available evidence level is "Humane RCT" for Linaclotid and "Humane studie" for Semax. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Linaclotid and Semax in Germany and the United States?: Duitsland: Linaclotid — Op recept, Semax — Niet goedgekeurd. Verenigde Staten: Linaclotid — Op recept, Semax — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.

Country

Linaclotid

Semax

Duitsland

Op recept

Niet goedgekeurd

—

Op recept

Verenigde Staten

Op recept

Niet goedgekeurd

Frequently asked questions

What is the difference between Linaclotid and Semax?

Linaclotid is classified as "Onderzoek (overig)", while Semax is classified as "Onderzoek (overig)". Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Semax: Synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10). Approved in Russia for ischaemic stroke, cognitive function and ADHD in children. Western phase-3 trials absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Linaclotid or Semax?

The highest available evidence level is "Humane RCT" for Linaclotid and "Humane studie" for Semax. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Linaclotid and Semax in Germany and the United States?

Duitsland: Linaclotid — Op recept, Semax — Niet goedgekeurd. Verenigde Staten: Linaclotid — Op recept, Semax — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.